"Glycorex had a strong second quarter of 2022 with solid double-digit growth. Demand grew as the effects of the COVID-19-pandemic continued to subside which, combined with an effective implementation of the company's G4G strategy, delivered a very good quarter."  - Geert Nygaard, CEO

Financial information

• Net sales: SEK 11.2 million (8.0)
• Operating income: SEK -1.7 million (-2.2)
• Net income for the period: SEK -1.7 million (-2.3)
• Earnings per share: SEK -0.02 (-0.03)

• Distributor agreement in Chile. Initiated marketing efforts.
• Registration of Glycosorb® ABO in South Africa. First order for Glycosorb® ABO from distributor.
• New transplant centers added in England and India.
• Participation as an exhibitor at the ATC (American Transplant Congress) in Boston.
• Indian customer reports successful blood group incompatible liver transplantation from a living donor using Glycosorb® ABO.
• Order of Glycosorb® ABO from reputable centers in England for the treatment of Pure Red Cell Aplasia after a blood group incompatible bone marrow transplant.
• Meetings with potential Glycosorb® UBP key customers in key European markets.
• Delivery of the Glycosorb® UBP to two European reference centers for evaluation.
• Positive initial results obtained for the reduction of anti-A/B antibodies on platelet concentrate. 
• Announcement of partner in the Rheumatoid Arthritis project.

• The CEO of Glycorex Transplantation AB (publ) resigns his employment.

THE ENTIRE INTERIM REPORT FOR QUARTER 2 2022 IS ATTACHED

For further information, please contact:

Glycorex Transplantation AB (publ)

Scheelevägen 27

SE-223 63 Lund, Sweden

Phone: +46 46 286 5230

info@glycorex.com

glycorex.com

This information is such information that Glycorex Transplantation AB is required to disclose in accordance with the EU Market Abuse Regulation. The information was submitted for publication on August 26, 2022 at 08.00 CET.

Brief information about the company

Glycosorb® ABO is one of Glycorex Transplantation AB's self-developed proprietary medical devices that is used clinically in four continents to facilitate blood group-compatible transplants, especially in kidney transplants from related living donors, but the product is also used in liver, heart, lung and stem cell transplantation. The product has so far been used in more than 5,000 kidney transplants. The short-term and long-term results are excellent. The results have been presented in over 60 scientific articles in reputable medical journals. Each kidney transplant has been estimated to save up to SEK 5 million in dialysis costs alone. Each kidney transplant saves about 150 dialysis treatments per year, meaning that the over 5,000 kidney transplants performed after Glycosorb® treatments, can be estimated to save over 700,000 dialysis treatments per year. In addition to Europe, the product is used in India, Canada, Israel, Singapore, Thailand, Mexico and Australia, for example.

The company has also developed a CE-marked medical device for the development of universal blood plasma and are developing products for the specific reduction of autoantibodies in the treatment of autoimmune diseases, as well as products for specific reduction of galectins. The company also develops products for the simultaneous reduction of blood group A/B specific antibodies and HLA antibodies (tissue-specific antibodies). The company is collaborating with a leading European research institute to develop a product for the treatment of the autoimmune disease rheumatoid arthritis. There are approximately 5 million patients in the EU who have this disease.

Glycorex Transplantation AB (publ) is listed on NGM Main Regulated Equity (Nordic Growth Market) and is traded under the symbol GTAB B.